(Peer-Reviewed) Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
Chunlong Ma, Haozhou Tan, Juliana Choza, Yuying Wang, Jun Wang 王俊
Department of Pharmacology and Toxicology, College of Pharmacy, the University of Arizona, Tucson, AZ 85721, USA
Acta Pharmaceutica Sinica B, 2021-11-01
Abstract
SARS-CoV-2 main protease (Mᵖʳᵒ) is one of the most extensively exploited drug targets for COVID-19. Structurally disparate compounds have been reported as Mᵖʳᵒ inhibitors, raising the question of their target specificity. To elucidate the target specificity and the cellular target engagement of the claimed Mᵖʳᵒ inhibitors, we systematically characterize their mechanism of action using the cell-free FRET assay, the thermal shift-binding assay, the cell lysate Protease-Glo luciferase assay, and the cell-based FlipGFP assay.
Collectively, our results have shown that majority of the Mᵖʳᵒ inhibitors identified from drug repurposing including ebselen, carmofur, disulfiram, and shikonin are promiscuous cysteine inhibitors that are not specific to Mᵖʳᵒ, while chloroquine, oxytetracycline, montelukast, candesartan, and dipyridamole do not inhibit Mᵖʳᵒ in any of the assays tested. Overall, our study highlights the need of stringent hit validation at the early stage of drug discovery.
3D imaging lipidometry in single cell by in-flow holographic tomography
Daniele Pirone, Daniele Sirico, Lisa Miccio, Vittorio Bianco, Martina Mugnano, Danila del Giudice, Gianandrea Pasquinelli, Sabrina Valente, Silvia Lemma, Luisa Iommarini, Ivana Kurelac, Pasquale Memmolo, Pietro Ferraro
Opto-Electronic Advances
2022-08-25
Natural history and cycle threshold values analysis of COVID-19 in Xiamen City, China
Bin Deng, Weikang Liu, Zhinan Guo, Li Luo, Tianlong Yang, Jiefeng Huang, Buasiyamu Abudunaibi, Yidun Zhang, Xue Ouyang, Demeng Wang, Chenghao Su, Tianmu Chen
Infectious Disease Modelling
2022-08-09